Head-to-head comparison
Retatrutide vs Tirzepatide
Physician-reviewed comparison
Retatrutide
Clinical DataResearch Only
Investigational triple receptor agonist showing the largest Phase 2 weight reductions reported to date.
Tirzepatide
Peer ReviewedFDA Approved
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management.
Quick Comparison
| Dimension | Retatrutide | Tirzepatide |
|---|---|---|
| Category | glp1 | glp1 |
| Classification | Triple Agonist (GLP-1 / GIP / Glucagon) | Dual GIP/GLP-1 Receptor Agonist |
| Evidence Rating | Clinical Data | Peer Reviewed |
| Regulatory Status | Research Only | FDA Approved |
| Delivery | Subcutaneous injection | Subcutaneous injection |
| Complexity | 5 / 5 | 4 / 5 |
| Refrigeration | Required | Required |
Dosing Comparison
Retatrutide
Phase 2 Obesity Trial
1–12 mg · weekly
Tirzepatide
Weight Loss (Zepbound)
2.5–15 mg · weekly
Type 2 Diabetes (Mounjaro)
2.5–15 mg · weekly
Can You Stack Them?
No known direct interaction between Retatrutide and Tirzepatide in our database. However, always consult your provider before combining compounds.
Medical Disclaimer
This comparison is for educational purposes only. Individual responses vary. Consult a qualified healthcare provider before using any compound.